HAVN Life Sciences Inc.
HAVN Life Sciences Inc.
Your view on HAVLF
Overview
What the company does, where it operates, and who runs it.
About HAVN Life Sciences Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Tim Moore
- Headquarters
- 22071 Fraserwood Way, Port Moody, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Tim Moore
- Headquarters
- 22071 Fraserwood Way, Port Moody, BC, CA
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp.
mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for HAVN Life Sciences Inc., and the rating behind it. HAVLF last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for HAVN Life Sciences Inc.. Starting points for HAVN Life Sciences Inc.: EPS -$5.25, beta -0.42 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for HAVN Life Sciences Inc.. HAVN Life Sciences Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for HAVN Life Sciences Inc.. Trailing twelve-month EPS for HAVN Life Sciences Inc. stands at -$5.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for HAVN Life Sciences Inc.. HAVN Life Sciences Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
HAVN Life Sciences Inc. valued side by side against its closest peers. HAVN Life Sciences Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold HAVN Life Sciences Inc., and how their positions are changing. At a $2,565 market value, institutional positions materially move HAVN Life Sciences Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by HAVN Life Sciences Inc. executives and directors. Shares of HAVN Life Sciences Inc. have traded between $0.0000 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming HAVN Life Sciences Inc.. HAVN Life Sciences Inc. is a $2,565 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming HAVN Life Sciences Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for HAVN Life Sciences Inc.. Coverage tracks HAVN Life Sciences Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.